Objective: Hybrid closed-loop (HCL) devices can achieve tight glycemic control but are rarely used in pregnancy, which remains an off-label indication. We present a case of a pregnant patient with type 1 diabetes mellitus (T1DM) who used the Medtronic MiniMed 670G HCL system.
Methods: MiniMed 670G includes an advanced automode option (HCL therapy), which our patient used from the first trimester to the end of the pregnancy.
Results: An unplanned pregnancy was detected in the T1DM patient, with a glycated hemoglobin level of 8.7 mmol/L (7.1%). The patient started sensor-augmented pump therapy at week 13. Subsequently, she entered automode (HCL) at week 16. The time in range (3.7-7.8 mmol/mol, 63-140 mg/dL) increased from 46.8% to 51.3% after HCL initiation. The glycated hemoglobin level remained close to 48 mmol/mol (6.5%) until the end of the pregnancy. Furthermore, the time under range (<3.7 mmol/mol, <63 mg/dL) remained below the optimal 4% level during the gestation. Finally, a healthy male baby was born at week 37. No safety events were recorded.
Conclusion: This case represents the successful off-label use of HCL during pregnancy in a patient with T1DM.
Keywords: HCL, hybrid closed-loop; HbA1c, glycated hemoglobin; MM670G, Medtronic MiniMed 670G; RT-CGM, real-time continuous glucose monitoring; T1DM, type 1 diabetes mellitus; TIR, time in range; TUR, time under range; closed-loop; pregnancy; type 1 diabetes mellitus.
© 2021 AACE. Published by Elsevier Inc.